TVB 2640

Drug Profile

TVB 2640

Alternative Names: TVB-2640

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 3-V Biosciences
  • Developer 3-V Biosciences; University of Kentucky; University of Texas Health Science Center at San Antonio
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Astrocytoma
  • Phase I/II Metabolic syndrome
  • Phase I Colorectal cancer; Solid tumours

Most Recent Events

  • 09 Jun 2017 Mayo Clinic plans a phase II trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (NCT03179904)
  • 01 Jun 2017 3-V Biosciences completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Monotherapy, Second-line therapy or greater) in USA and United Kingdom (PO) (NCT02223247)
  • 18 May 2017 Phase-II clinical trials in Astrocytoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03032484)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top